EMG
TBPH icon

Ellington Management Group’s Theravance Biopharma TBPH Stock Holding History

Ellington Management Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-9,200
Closed -$209K – 697
2016
Q2 		$209K Buy
+9,200
New +$199K 0.29% 135

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's TBPH Position: Q3 2016 in Review

Ellington Management Group sold out of Theravance Biopharma (TBPH) in Q3 2016, closing a stake of 9,200 shares — an estimated $209K sold.

Ellington Management Group first reported a position in TBPH in Q2 2016 and held it in 1 quarter. The position peaked at $209K in Q2 2016. 100 funds tracked by Wall St. Rank hold TBPH as of Q3 2016.

  • Ellington Management Group reported no remaining Theravance Biopharma position as of Q3 2016 after selling out during the quarter.
  • Ellington Management Group sold 9,200 Theravance Biopharma shares in Q3 2016, an estimated $209K.
  • Ellington Management Group first reported a position in Theravance Biopharma in Q2 2016 and held it in 1 quarter.
  • Ellington Management Group's Theravance Biopharma position peaked at $209K in Q2 2016.
  • 100 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2016.

Based on Ellington Management Group's 13F filing for Q3 2016, filed 14 Nov 2016.